Horizon 2020 Framework Programme for Research and Innovation (2014-2020)
The consortium name ‘MultipleMS’ refers to the disease Multiple Sclerosis, the multiple manifestations thereof and to the size and multiplicity of the partnership. In this project, universities and companies across 11 European countries and the US will unite efforts to tailor the development and application of therapies to the individual MS patient. Behind the scenes we are working on the required approvals, data transfer agreements and database solutions. In September 2020, we completed inclusion of 500 patients that will be followed over at least two years, whilst analysis of already existing data across centres is in advanced stages.
MultipleMS & Covid-19 - update
The global outbreak of Covid-19 has had an impact on all medical activities across the world, including at the MultipleMS inclusion- and follow up centres. At the majority of our inclusion centres, new routines are in place to warrant the safety of both patients and researchers. Our studies proceed as close to the original planning as feasible, whilst the analyses and discussions of these are now mainly performed using remote tools. In spite of delays caused by the acute phase of the global outbreak, we remain dedicated to reaching our study end points. We refer our study patients to their respective inclusion centres for an up-to-date overview of the local routines.
MultipleMS prospective study inclusions completed
In January 2018, the MultipleMS consortium included the first patients in an extensive and ambitious prospective study across multiple European study centers. In September 2020, the goal of 500 required patients was reached. This is a major milestone in our project, and whilst the first patients in this prospective study have already completed their 24-month follow up visits, in two years from today the prospective study is concluded with the last 24-month visit. In the meantime, the consortium is working hard to extend the follow up of included patients, since this is valuable and important data. Several initiatives are launched to fund a 36-month follow up, and hopefully additional future visits.
In parallel with our prospective study mentioned above, several other projects are advancing in which researchers across the consortium are analyzing already existing data collected from all participating and collaborating clinical centers.
In the photo the current coordinators of the prospective study from "The Technical University of Munich, Germany"
MultipleMS & Covid-19
The global outbreak of Covid-19 has had an impact on all medical activities across the world, including at the MultipleMS inclusion- and follow up centres. Nevertheless, the prospective study is currently following its projected course, with only minor delays for visits that were planned during the acute phase of the pandemic. Each centre has its own local guidelines under which the patients' follow up is secured and safe.
Face-to-face meeting Stockholm
The yearly general assemble meeting is ongoing in Stockholm. A large part of the active collaborating parties in MultipleMS is presenting their status updates and future plans. Most of the participants will continue this week with the yearly ECTRIMS conference.
First Norwegian prospective cohort patient included.
We have finally received all required approvals to start collecting newly diagnosed patients. On the 8th of January 2018 the first Norwegian MS patient was included in the prospective cohort, which is at the core of the entire project. We will continue to collect at our inclusion sites across Europe until we reach a cohort of 500 newly diagnosed patients, all of whom will be followed closely with our harmonised protocols for data collection.
'Why' MultipleMS - our collective mission statement
“We believe that multiple sclerosis (MS) can be beaten. We are a diverse group of scientists and physicians with a common goal: to improve the lives of people with MS. In the MultipleMS project, we will weave together the unique medical histories of each person with MS to paint a detailed molecular portrait of the disease. Over the next five years we will use this molecular portrait to develop new ways to stop the disease in its tracks and develop protocols for choosing therapies for each individual patient” The MultipleMS consortium
'Why' MultipleMS - Wouter Jansen, PhD
“As innovation advisor in MultipleMS, I am keen to help connecting bright people with bright ideas and create an innovative, trusted, and inspiring environment to bring those ideas to life.” Wouter Jansen, Innovation Manager of MultipleMS, PwC
'Why' MultipleMS - Professor Jasper Tegner
“In MultipleMS we have a unique opportunity to develop and apply powerful algorithms for integrating rich data from DNA to patient records, enabling a more personalized and preventive approach for patients suffering from Multiple Sclerosis” Jesper Tegnér, Chaired Strategic Professor in Computational Medicine, YouHealth (Sweden).
'Why' MultipleMS - Ass. Professor Chris Cotsapas
“We take on the hardest and most pressing problems in human disease, and bring whatever resources and methods are required to bear on them. We consider our inability to predict an individual’s disease course and response to therapy in MS unacceptable, and participate in theMultipleMS project to solve this problem.” Chris Cotsapas, Associate Professor of Neurology and of Genetics (Yale University School of Medicine, USA)
'Why' MultipleMS - Professor Sergio Baranzini
“Although we live in the information age, integration and contextualization of this information has consistently been realized at a much slower pace in the healthcare space than in financial, consumer or retail industries. This is due in part to the enormous complexity of the biological systems underlying the human body, but also due to the lack of standardization and cooperation across research teams doing similar work. MultipleMS is an important step in that direction and it will provide a platform for researchers and patients with MS to advance personalized medicine together”
Sergio Baranzini, Professor at UCSF, USA.
'Why' MultipleMS - Professor Hanne F. Harbo
“As a neurologist I regularly meet persons suffering from MS, who I aim to treat and help in the best possible way. By contributing to this cutting edge MultipleMS research project, I hope we will bring this field an important step forward. This project allows us to analyze multiple facets of MS in close collaboration with well-established successful consortia and excellent researchers worldwide, giving us a great opportunity to exploit and implement novel research to the best of our patients, their families and other stakeholders."
Hanne Flinstad Harbo, Professor of Neurology, University of Oslo/Oslo University Hospital
'Why' MultipleMS - Ass. Prof. Maja Jagodic
“I have always been fascinated by the complexity of the human body and how devastating the consequences of tipping a balance between a myriad of functions can be. Understanding this complexity, no matter how challenging, is the only way to truly make a difference for people who suffer from debilitating diseases such as MS. This is what MultipleMS is for me.”
Maja Jagodic, Karolinska Institutet, Sweden.
Project leader professor Ingrid Kockum (Karolinska Institutet, Sweden) about why MultipleMS is important:
“I am excited about the MultipleMS project since I think that we will be able to address research questions that we have not been able to address efficiently previously through collaboration between researchers with unique experiences and because we are utilizing data from different fields in joint analyses.
I am motivated to carry out this project because I believe that it will result in real progress in understanding aspects of Multiple Sclerosis pathogenesis which can be used for improvement of treatment of Multiple Sclerosis.”